CoChat

Spironolactone versus eplerenone for the treatment of idiopathic hyperaldosteronism

Karagiannis, Asterios, Tziomalos, Konstantinos, Papageorgiou, Athanasios, Kakafika, Anna I, Pagourelias, Efstathios D, Anagnostis, Panagiotis, Athyros, Vasilios G, Mikhailidis, Dimitri P · 2008 · Expert Opinion on Pharmacotherapy
Cited by 133

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Abstract

The aim of this prospective, randomised, open-label, blinded-end point study was to compare the efficacy and safety of eplerenone versus spironolactone in patients with bilateral idiopathic hyperaldosteronism (IHA). After a 2-week washout period, 34 patients with IHA were assigned to receive either spironolactone 25 mg b.i.d. (n = 17) or eplerenone 25 mg b.i.d. (n = 17) for 24 weeks. If the patients' blood pressure (BP) was not < 140/90 mmHg, the doses were gradually increased up to 400 mg for spironolactone and 200 mg for eplerenone. If the patients' BP remained uncontrolled, a daily dose of hydrochlorothiazide 12.5 mg was added at week 16. The primary outcome was the percentage of patients with BP < 140/90 mmHg at 16 weeks (i.e., with aldosterone antagonist monotherapy). The patients' BP was normalised in 13 out of 17 (76.5%) and 14 out of 17 (82.4%) patients in the spironolactone and eplerenone groups, respectively (p = 1.00). Systolic BP decreased more rapidly with eplerenone. Serum potassium levels were normalised (> 3.5 mmol/l) in all patients at 4 weeks. Mild hyperkalaemia was observed in two patients receiving 400 mg of spironolactone and in three patients receiving 150 mg of eplerenone. Two patients presented with bilateral painful gynaecomastia at the end of week 16 while receiving 400 mg of spironolactone. Switching spironolactone to 150 mg of eplerenone daily resulted in resolution of gynaecomastia and also maintained BP control. At the end of the study, 19 patients were on eplerenone and 15 were on spironolactone. However, this did not affect the primary end point, because the switch from spironolactone to eplerenone (in two patients) occurred at the end of week 16. It was concluded that eplerenone was as effective as spironolactone in reducing BP in patients with IHA. The risk of mild hyperkalaemia was similar with both drugs.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1517/14656566.9.4.509

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 3 references

Cited by

See all 133

Metadata

Authors
Karagiannis, A., Tziomalos, K., Papageorgiou, A., Kakafika, A. I., Pagourelias, E. D., Anagnostis, P., Athyros, V. G., & Mikhailidis, D. P.
Venue
Expert Opinion on Pharmacotherapy
Published
2008-03
Volume
9
Issue
4
Pages
509-515
ISSN
  • 1465-6566 (ISSN-L)
  • 1744-7666
OpenAlex
W2019439141
Cited by
133
References
3
FWCI
8.28
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Spironolactone versus eplerenone for the treatment of idiopathic hyperaldosteronism. https://app.cochat.ai/papers/10.1517/14656566.9.4.509
The paper
Karagiannis, A., Tziomalos, K., Papageorgiou, A., Kakafika, A. I., Pagourelias, E. D., Anagnostis, P., Athyros, V. G., & Mikhailidis, D. P. (2008). Spironolactone versus eplerenone for the treatment of idiopathic hyperaldosteronism. Expert Opinion on Pharmacotherapy. https://doi.org/10.1517/14656566.9.4.509

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.